Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Animals
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Pharmacological
Carcinoma, Non-Small-Cell Lung
/ immunology
Costimulatory and Inhibitory T-Cell Receptors
/ antagonists & inhibitors
Humans
Immunotherapy
/ methods
Lung Neoplasms
/ immunology
Patient Selection
Risk Assessment
Treatment Outcome
NSCLC
benefits
challenges
immune checkpoint inhibitors
non-small-cell lung cancer
Journal
Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
31
7
2019
medline:
28
5
2020
entrez:
31
7
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). It has improved the overall survival in the first- and second-line setting with manageable adverse events. Multiple challenges still impede the success of ICI in the whole population of NSCLC namely the lack of reliable predictive biomarkers, the scarcity of data regarding the optimal treatment duration with ICI and possibility of rechallenge with ICI as well as the efficacy of ICI in special subgroups of patients such as those with oncogenic addicted tumors or patients with brain metastases. In this framework, we review the benefits and challenges of ICI in NSCLC, in monotherapy and in combinations, in the advanced setting.
Identifiants
pubmed: 31361172
doi: 10.2217/imt-2019-0071
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Pharmacological
0
Costimulatory and Inhibitory T-Cell Receptors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM